CTS

CTS Corporation

$63.89 -0.50%

Recent alerts on CTS

All signals →

SEC filing CTS Shareholders Elect 8 Directors, Approve Executive Compensation 94%, Ratify Grant Thornton Auditor 98%

News CTS outlines 2026 guidance of $560M-$580M sales and $2.35-$2.45 adjusted EPS as diversified markets grow 18%

Insider trade Sale by Ashish Agrawal (CFO)

News Is Kulicke and Soffa Stock a Buy or Sell After the CTO Sold Over 7,000 Shares?

News Is Kulicke and Soffa Stock a Buy or Sell After the CTO Sold Over 7,000 Shares?

News CTS targets $550M–$580M 2026 revenue while advancing diversification and medical growth

News CTS Corporation beats top-line and bottom-line estimates; initiates FY26 outlook

SEC filing CTS Presents Q4 2025 Revenue of $1.5B, EPS of $3.10, Outlines FY26 Growth Targets

News Cintas (CTAS) Targets Operational Leverage Through Expanded Customer Footprint

News EQS-PVR: CTS Eventim AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution – Company Announcement - FT.com

News Exclusive: Meta's new AI team delivered first key models internally this month, CTO says

News S&P 500: Carry Trade Unwind Signals More Volatility Ahead

News Cintas Corporation (CTAS): A Bull Case Theory

News 2 Magnificent S&P 500 Dividend Stocks Down 10% and 14% to Buy Right Now for 2026

News Wells Fargo Boosts Centuri Holdings (CTRI) PT to $30 Despite Expected Sector Slowdown

News Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

News UK and EU regulators sign Memorandum of Understanding to strengthen oversight of critical third parties

News Deadline Alert: CTO Realty Growth, Inc. (CTO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

News Deadline Soon: CTO Realty Growth, Inc. (CTO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

News UniFirst Confirms Receipt of Unsolicited, Non-Binding Proposal from Cintas Corporation

News Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Scanner Unusual volume (z=5.2)

Scanner Unusual volume (z=4.8)

News UniFirst Confirms Receipt of Unsolicited, Non-Binding Proposal from Cintas Corporation

Scanner Unusual volume (z=4.8)

Get push alerts for CTS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS